antibiot
stewardship
antivir
influenza
rapid
test
hospit
admiss
retrospect
cohort
design
use
studi
impact
multiplex
respiratori
viru
panel
polymeras
chain
reaction
test
adult
patient
suspect
influenzalik
ill
decis
regard
continu
empir
antivir
therapi
appear
impact
test
howev
impact
reduc
antibiot
use
remain
unclear
respiratori
tract
infect
common
manifest
wide
rang
symptom
often
difficult
distinguish
viral
bacteri
etiolog
clinic
ground
alon
howev
rapid
accur
etiolog
identif
import
guid
patient
manag
henc
reduc
morbid
mortal
implement
appropri
infect
control
practic
target
therapi
expect
decreas
risk
emerg
drugresist
bacteri
strain
nosocomi
infect
clostridium
difficil
context
limit
health
care
resourc
interest
assess
impact
respiratori
viru
diagnost
test
antimicrobi
therapi
nucleic
acid
amplif
test
consid
gold
standard
respiratori
viru
test
inhous
multiplex
revers
transcript
polymeras
chain
reaction
mrvp
simultan
detect
identifi
respiratori
viru
target
influenza
influenza
b
parainfluenza
adenoviru
rhinoviru
enteroviru
coronaviru
type
respiratori
syncyti
viru
human
metapneumoviru
excel
turnaround
time
hour
use
sinc
mcgill
univers
health
centr
object
studi
evalu
impact
mrvp
test
use
antivir
antimicrobi
therapi
among
adult
patient
hospit
set
either
emerg
room
inpati
suspect
influenzalik
ill
studi
design
retrospect
cohort
studi
conduct
among
adult
patient
emerg
depart
inpati
peak
influenza
season
similar
mani
hospit
center
canada
mcgill
univers
health
centr
emerg
room
includ
hold
area
intern
medicin
patient
includ
sick
patient
observ
admit
patient
wait
bed
length
stay
patient
averag
hour
polymeras
chain
reaction
test
indic
patient
like
admit
risk
complic
mrvp
test
carri
use
autom
specimen
extract
nuclisen
extractor
franc
simultan
amplif
respiratori
virus
lightcycl
roch
appli
system
penzberg
upper
bavaria
germani
assay
valid
field
test
see
supplementari
appendix
detail
januari
march
adult
patient
suspect
influenzalik
ill
test
posit
mrvp
posit
influenza
respiratori
viru
enrol
expos
group
effici
patient
either
emerg
depart
patient
inpati
neg
mrvp
test
studi
period
equal
number
patient
n
randomli
select
within
time
frame
expos
group
clinic
data
includ
demograph
characterist
comorbid
present
absent
patient
locat
time
mrvp
test
prescript
antibiot
antivir
chest
radiograph
result
collect
medic
chart
use
antibiot
consid
potenti
prescrib
respiratori
bacteri
infect
name
ceftriaxon
doxycyclin
azithromycin
piperacillintazobactam
fluoroquinolon
moxifloxacin
record
patient
classifi
accord
mrvp
result
follow
group
influenza
posit
noninfluenza
posit
neg
virus
compar
clinic
characterist
patient
group
calcul
differ
mean
continu
characterist
differ
proport
categor
characterist
togeth
confid
interv
evalu
whether
mrvp
test
result
associ
chang
manag
antivir
antibiot
treatment
see
definit
supplementari
appendix
stratifi
patient
locat
also
evalu
associ
mrvp
decis
admit
patient
emerg
room
set
analys
perform
use
ibm
spss
window
ibm
armonk
ny
select
patient
half
men
tabl
averag
patient
posit
influenza
group
younger
neg
influenza
group
differ
mean
year
confid
interv
posit
noninfluenza
group
differ
mean
year
confid
interv
patient
test
posit
group
like
present
fever
cough
test
neg
percentag
patient
comorbid
high
group
percentag
patient
suspect
pneumonia
base
chest
radiographi
result
similar
group
seventi
percent
patient
posit
result
onethird
patient
neg
result
treat
emerg
room
wherea
rest
hospit
time
test
polymeras
chain
reaction
test
result
avail
day
patient
next
day
remain
patient
result
avail
patient
studi
prior
discharg
hospit
among
hospit
patient
patient
posit
influenza
empir
treat
oseltamivir
antivir
prior
test
result
continu
treatment
given
mrvp
test
result
tabl
neg
mrvp
result
empir
oseltamivir
antivir
treatment
discontinu
twothird
hospit
patient
empir
oseltamivir
antivir
treatment
also
discontinu
hospit
patient
posit
noninfluenza
result
proport
empir
antibiot
treatment
hospit
patient
patient
neg
mrvp
test
patient
posit
noninfluenza
patient
posit
influenza
empir
antibiot
treatment
continu
hospit
patient
neg
mrvp
test
empir
antibiot
treatment
discontinu
onequart
ie
mrvpposit
hospit
patient
stratifi
hospit
mrvpposit
patient
accord
whether
suspect
pneumonia
found
patient
suspect
pneumonia
continu
empir
antibiot
compar
note
valu
n
otherwis
indic
mrvp
multiplex
revers
transcript
polymeras
chain
reaction
na
applic
chest
radiograph
result
miss
patient
posit
influenza
posit
noninfluenza
neg
categori
respect
result
miss
patient
among
influenzaneg
categori
patient
suspect
pneumonia
high
preval
comorbid
permit
stratifi
analysi
influenzaposit
patient
treat
empir
highli
like
initi
test
result
among
hospit
patient
among
emerg
room
patient
schedul
admit
among
patient
neg
mrvp
test
empir
treat
antibiot
treatment
initi
patient
set
hospit
patient
emerg
room
patient
among
patient
test
emerg
room
mrvpposit
patient
admit
compar
mrvpneg
patient
find
show
antivir
manag
gener
appropri
influenza
season
mrvp
result
admit
patient
posit
influenza
continu
empir
oseltamivir
antivir
treatment
high
proport
patient
neg
result
patient
noninfluenza
posit
result
discontinu
treatment
antivir
initi
admit
patient
posit
influenza
empir
treat
impact
mrvp
test
antibiot
manag
less
evid
seventi
percent
patient
ward
turn
posit
influenza
empir
treat
antibiot
quarter
discontinu
treatment
given
mrvp
result
suspicion
concomit
presenc
secondari
bacteri
infect
like
explan
continu
antibiot
case
howev
small
sampl
size
studi
preclud
abil
studi
hypothesi
greater
depth
moreov
introduct
use
interpret
mrvp
test
rel
new
institut
clinic
practic
may
chang
yet
nonetheless
mrvpposit
result
emerg
room
set
appear
associ
discharg
hospit
nonrandom
studi
design
drawback
differ
mrvpposit
mrvpneg
patient
may
attribut
differ
distribut
import
confound
factor
eg
age
comorbid
could
analyz
role
comorbid
continu
use
antibiot
antivir
almost
treat
patient
comorbid
futur
studi
finer
definit
comorbid
suspicion
bacteri
respiratori
infect
would
need
investig
reason
continu
antibiot
use
anoth
limit
work
abl
measur
impact
mrvp
test
infect
control
lack
individuallevel
data
initi
measur
conclud
mrvp
test
could
potenti
posit
impact
clinic
manag
respiratori
viral
infect
adult
patient
howev
impact
reduc
antibiot
use
remain
unclear
find
support
concept
viral
respiratori
tract
infect
common
caus
inappropri
antibiot
usag
target
educ
antibiot
stewardship
program
